Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.

PloS one - 1 Jan 2014

Siebert Nikolai, Seidel Diana, Eger Christin, Jüttner Madlen, Lode Holger N

Abstract excerpt

Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option to improve outcome. After establishing a production process in Chinese hamster ovary (CHO) cells, ch14.18/CHO was made available in Europe for clinical trials. Here, we describe validated functional bioassays for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody-Dependent Cell Cytotoxicity
Share to Antigens, Surface

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Cytotoxicity, Immunologic

Share to Cytotoxicity Tests, Immunologic

Share to Gangliosides

Share to Leukocyte Count

Share to Quality Control

Source

Open in PubMed Open full text

Identifiers

PMID: 25226154
DOI: 10.1371/journal.pone.0107692
PMCID: PMC4167242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.PMID 25226154Read ↗

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHOSemantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patientsSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read ↗

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trialSemantic proximity Read ↗

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blastsSemantic proximity Read ↗

Functional Parameters of Hybridoma Cells: Methods of Evaluation and Biotechnological RelevanceSemantic proximity Read ↗

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Semantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.